Status:
COMPLETED
A Real-world Study of Imraldi® Use
Lead Sponsor:
Biogen
Conditions:
Arthritis, Rheumatoid (RA)
Axial Spondyloarthritis (axSpA)
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this study is to evaluate candidate predictors of persistence on adalimumab (Imraldi®) participants diagnosed with immune-mediated inflammatory disease in Europe (EU). The se...
Eligibility Criteria
Inclusion
- Initiation on Imraldi® therapy after 18th October 2018, as part of routine treatment immediately after transitioning from at least 16 weeks' treatment with originator adalimumab (Humira®)
- Availability of at least one Baseline disease score (i.e. within 16 weeks prior or up to 6 weeks post-initiation of Imraldi®)
- Should provide informed consent to participate in the study
Exclusion
- \- Unlikely to attend for regular clinic visits for the duration of study follow-up, in the opinion of the Investigator
Key Trial Info
Start Date :
June 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2021
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04089514
Start Date
June 30 2019
End Date
November 30 2021
Last Update
April 18 2023
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bruges, Belgium
2
Research Site
Brussels, Belgium
3
Research Site
Genk, Belgium
4
Research Site
Ghent, Belgium